Cingulate Amends S-1, Delays Offering for Continuous Sale
Ticker: CINGW · Form: S-1/A · Filed: Jul 25, 2025 · CIK: 1862150
| Field | Detail |
|---|---|
| Company | Cingulate Inc. (CINGW) |
| Form Type | S-1/A |
| Filed Date | Jul 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, SEC Filing, Pharmaceuticals, Emerging Growth Company, Capital Raise, Continuous Offering, Regulatory Compliance
Related Tickers: CINGW
TL;DR
**CINGW's S-1/A is a non-event, just a procedural delay for future share sales, so don't expect immediate market impact.**
AI Summary
Cingulate Inc. filed an S-1/A on July 25, 2025, for the continuous offering of securities by a selling stockholder, indicating no immediate revenue or net income changes but rather a procedural update for capital raising. The company, classified as a non-accelerated filer, smaller reporting company, and emerging growth company, is based in Kansas City, KS, and operates in the pharmaceutical preparations industry (SIC 2834). This amendment primarily serves to delay the effective date of the registration statement, allowing for a 'from time to time' sale of securities. Key business changes are not detailed in this specific amendment, which focuses on regulatory compliance for future offerings. Risks include those inherent to an emerging growth company in the pharmaceutical sector, particularly regarding the successful development and commercialization of drug candidates. The strategic outlook remains focused on leveraging its status to access capital markets as needed, without specifying new product developments or market expansions in this filing.
Why It Matters
This S-1/A filing is a procedural step for Cingulate Inc. to maintain flexibility in raising capital, allowing a selling stockholder to offer securities 'from time to time.' For investors, it signals potential dilution if new shares are issued, but also the company's ongoing efforts to secure funding for its pharmaceutical development. Employees and customers are not directly impacted by this administrative filing, but the ability to raise capital is crucial for the company's long-term viability and project funding. In the competitive pharmaceutical market, continuous access to capital is vital for smaller reporting companies like Cingulate to fund R&D and compete with larger, more established players.
Risk Assessment
Risk Level: medium — Cingulate Inc. is classified as a 'smaller reporting company' and an 'emerging growth company,' indicating inherent risks associated with early-stage pharmaceutical companies, including reliance on future capital raises and successful drug development. The continuous offering of securities by a selling stockholder, as outlined in the S-1/A, introduces potential for future dilution, which could negatively impact existing shareholders.
Analyst Insight
Investors should monitor Cingulate Inc.'s future filings for details on the actual sale of securities and any associated dilution. Given its status as an emerging growth company, consider this a long-term, high-risk investment and evaluate its drug pipeline and clinical trial progress before making any decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Shane J. Schaffer | Chief Executive Officer |
Key Numbers
- 333-288877 — Registration No. (SEC file number for the S-1/A filing)
- 2025-07-25 — Filing Date (Date the S-1/A was filed with the SEC)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 1901 W. 47th Place — Business Address (Principal executive offices of Cingulate Inc.)
- (913) 942-2300 — Business Phone (Contact number for Cingulate Inc.)
Key Players & Entities
- Cingulate Inc. (company) — Registrant and pharmaceutical preparations company
- Shane J. Schaffer (person) — Chief Executive Officer of Cingulate Inc.
- Michael J. Lerner, Esq. (person) — Counsel from Lowenstein Sandler LLP
- Steven M. Skolnick, Esq. (person) — Counsel from Lowenstein Sandler LLP
- Lowenstein Sandler LLP (company) — Legal counsel for Cingulate Inc.
- SEC (regulator) — Securities and Exchange Commission
- Kansas City, KS (company) — Location of Cingulate Inc.'s principal executive offices
- Delaware (company) — State of incorporation for Cingulate Inc.
- 03 Life Sciences (company) — Organization name associated with the filer
- 86-3825535 (dollar_amount) — I.R.S. Employer Identification Number for Cingulate Inc.
FAQ
What is the purpose of Cingulate Inc.'s S-1/A filing on July 25, 2025?
The S-1/A filing by Cingulate Inc. on July 25, 2025, is an amendment to its registration statement (No. 333-288877) to delay its effective date. This allows for a continuous offering of securities by a selling stockholder 'from time to time' under Rule 415 of the Securities Act of 1933.
Is Cingulate Inc. considered an emerging growth company?
Yes, Cingulate Inc. has indicated by check mark that it is an 'emerging growth company' as defined in Rule 12b-2 of the Exchange Act. This classification impacts its regulatory compliance requirements and reporting obligations.
What is Cingulate Inc.'s primary business industry?
Cingulate Inc.'s primary business industry is 'PHARMACEUTICAL PREPARATIONS,' as indicated by its Standard Industrial Classification (SIC) Code 2834. The company is focused on developing pharmaceutical products.
Who is the Chief Executive Officer of Cingulate Inc.?
Shane J. Schaffer is the Chief Executive Officer of Cingulate Inc. His contact information is listed as 1901 W. 47th Place, Kansas City, KS 66205, with a phone number of (913) 942-2300.
What is the address of Cingulate Inc.'s principal executive offices?
The principal executive offices of Cingulate Inc. are located at 1901 W. 47th Place, Kansas City, KS 66205. This address is also listed as the mailing address for the company.
What are the implications of Cingulate Inc. being a 'smaller reporting company'?
As a 'smaller reporting company,' Cingulate Inc. is subject to scaled disclosure requirements, which can reduce the burden of SEC compliance. This status is often associated with companies that have a public float of less than $250 million or annual revenues of less than $100 million.
Does this S-1/A filing indicate new revenue or net income for Cingulate Inc.?
No, this S-1/A filing is a procedural amendment related to the registration of securities for future sale by a selling stockholder. It does not contain information about Cingulate Inc.'s current revenue, net income, or other financial performance metrics.
What is the SEC file number for Cingulate Inc.'s registration statement?
The SEC file number for Cingulate Inc.'s registration statement, which this S-1/A amends, is 333-288877. This number identifies the specific filing with the Securities and Exchange Commission.
What is the potential impact of a continuous offering on Cingulate Inc. investors?
A continuous offering by a selling stockholder, as enabled by this S-1/A, could lead to potential dilution for existing Cingulate Inc. investors if new shares are sold into the market. This increases the number of outstanding shares, potentially decreasing the value of each existing share.
Who are the legal counsels listed for Cingulate Inc. in this filing?
Michael J. Lerner, Esq., and Steven M. Skolnick, Esq., both from Lowenstein Sandler LLP, are listed as legal counsels for Cingulate Inc. in this S-1/A filing. Their office is located at 1251 Avenue of the Americas, New York, New York 10020.
Risk Factors
- Continuous Offering Compliance [medium — regulatory]: The S-1/A filing is a procedural update to allow for the continuous offering of securities by a selling stockholder. This indicates a need for ongoing access to capital markets, which requires adherence to SEC regulations for delayed or continuous offerings under Rule 415.
- Drug Development and Commercialization [high — operational]: As an emerging growth company in the pharmaceutical sector, Cingulate Inc. faces inherent risks related to the successful development and commercialization of its drug candidates. The success of these candidates is critical for future revenue generation and market penetration.
- Reliance on Capital Markets [medium — financial]: The continuous offering mechanism suggests a potential reliance on capital markets for funding. This exposes the company to market volatility and the ability to raise capital at favorable terms, which can impact its operational capacity and growth trajectory.
Industry Context
Cingulate Inc. operates within the pharmaceutical preparations industry (SIC 2834). This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical giants and other emerging biotechs. Success hinges on innovation, clinical trial outcomes, and effective market access strategies.
Regulatory Implications
The S-1/A filing is a regulatory necessity for the continuous offering of securities. It ensures compliance with SEC rules, particularly Rule 415, for delayed offerings. Failure to adhere to these regulations could result in penalties or suspension of the offering.
What Investors Should Do
- Monitor future SEC filings for updates on drug development progress and clinical trial results.
- Assess the company's cash burn rate and its ability to access capital through the continuous offering mechanism.
Key Dates
- 2025-07-25: Filing of S-1/A Amendment No. 1 — This filing allows for the continuous offering of securities by a selling stockholder, indicating a strategy for ongoing capital raising and procedural compliance with SEC regulations for delayed offerings.
Glossary
- S-1/A
- An amendment to a Form S-1 registration statement filed with the SEC. It is used to update or correct information in the original filing or to delay the effective date of the registration statement. (This is the primary document type filed by Cingulate Inc., indicating a procedural step for registering securities for sale.)
- Rule 415
- SEC rule that permits the 'at-the-market' or continuous offering of securities over a period of time, rather than a single, fixed offering. (Cingulate Inc. is utilizing this rule, as indicated by the checkmark, to facilitate the 'from time to time' sale of securities by a selling stockholder.)
- Emerging Growth Company
- A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are eligible for certain regulatory and disclosure accommodations. (Cingulate Inc. self-identifies as an emerging growth company, suggesting it may benefit from reduced reporting requirements and compliance burdens.)
- Non-accelerated filer
- A filer that does not meet the thresholds for accelerated or large accelerated filer status, typically having less than $75 million in public float. (This classification indicates Cingulate Inc. is subject to less stringent SEC filing deadlines and disclosure requirements compared to larger companies.)
- Smaller Reporting Company
- A company that meets certain criteria related to public float and revenue, allowing for scaled-down disclosure requirements. (Similar to an emerging growth company, this status provides Cingulate Inc. with reduced reporting obligations.)
Year-Over-Year Comparison
This S-1/A filing on July 25, 2025, is a procedural amendment to a prior registration statement, primarily to facilitate a continuous offering of securities by a selling stockholder. It does not appear to introduce new financial data or significant business changes compared to a hypothetical prior filing. The focus remains on enabling future capital raising activities rather than reporting on past performance metrics like revenue growth or margin changes.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on July 25, 2025 by Shane J. Schaffer regarding Cingulate Inc. (CINGW).